Information Provided By:
Fly News Breaks for April 3, 2017
PTLA
Apr 3, 2017 | 05:37 EDT
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $51 saying recent Phase 3 successes should expand the indication set for approved novel oral anticoagulants. The analyst now sees a broader need for Portola's bleeding reversal agent AndexXa and believes approval is a matter of when, not if. He reiterates a Buy rating on the shares.
News For PTLA From the Last 2 Days
There are no results for your query PTLA